[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDURHrKzt7tHN5vUfsnsCe1Mhs1czBFyhzAnuEZEJHUo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":31,"phaseBuckets":32,"rows":39},"Glaxo Wellcome",[4],72,false,0,17,6704,[12,14,17,19,22,25,27,29],{"name":13,"count":6},"HIV Infections",{"name":15,"count":16},"Herpes Simplex",4,{"name":18,"count":16},"Pneumonia, Pneumocystis Carinii",{"name":20,"count":21},"AIDS Dementia Complex",2,{"name":23,"count":24},"Herpes Genitalis",1,{"name":26,"count":24},"Kidney Failure, Chronic",{"name":28,"count":24},"Toxoplasmosis, Cerebral",{"name":30,"count":24},"Cytomegalovirus Infections",[],[33,34,35,36,37,38],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[40,106,141,175,199,217,276,301,330,354,376,398,421,443,464,486,651,819,905,990,1041,1088,1130,1170,1204,1230],{"intervention":41,"totalTrials":42,"cells":43},"Efavirenz",5,{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":69,"PHASE4":71,"NA":104},{"trials":45,"activeCount":8},[],{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[50,60],{"nctId":51,"briefTitle":52,"status":53,"phases":54,"enrollment":55,"conditions":56,"interventions":57},"NCT00002213","The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors","COMPLETED",[35],80,[13],[58,59,41],"Abacavir sulfate","Amprenavir",{"nctId":61,"briefTitle":62,"status":53,"phases":63,"start":64,"conditions":65,"interventions":66},"NCT00004852","Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs",[35],"1999-09",[13],[41,67,68],"Lamivudine","Zidovudine",{"trials":70,"activeCount":8},[],{"trials":72,"activeCount":8},[73,84,94],{"nctId":74,"briefTitle":75,"status":53,"phases":76,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":81},"NCT00005018","Safety and Effectiveness of a Combination Anti-HIV Drug Treatment",[37],"2000-10","1999-07",150,[13],[82,58,41,83],"Hydroxyurea","Didanosine",{"nctId":85,"briefTitle":86,"status":87,"phases":88,"enrollment":89,"conditions":90,"interventions":91},"NCT00005017","Effectiveness and Safety of Epivir\u002FZiagen\u002FZerit (3TC\u002FABC\u002Fd4T) Versus Epivir\u002FZiagen\u002FSustiva (3TC\u002FABC\u002FEFV) Versus Epivir\u002FZiagen\u002FAgenerase\u002FNorvir (3TC\u002FABC\u002FAPV\u002FRTV) in HIV Patients Who Have Never Received Treatment","UNKNOWN",[37],300,[13],[92,58,59,41,67,93],"Ritonavir","Stavudine",{"nctId":95,"briefTitle":96,"status":53,"phases":97,"start":98,"enrollment":99,"conditions":100,"interventions":101},"NCT00004585","A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults",[37],"1999-10",40,[13],[102,103,58,41],"Abacavir sulfate, Lamivudine and Zidovudine","Lamivudine\u002FZidovudine",{"trials":105,"activeCount":8},[],{"intervention":93,"totalTrials":107,"cells":108},3,{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":124,"PHASE4":126,"NA":139},{"trials":110,"activeCount":8},[],{"trials":112,"activeCount":8},[],{"trials":114,"activeCount":8},[115],{"nctId":116,"briefTitle":117,"status":53,"phases":118,"start":119,"conditions":120,"interventions":121},"NCT00002442","A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs",[35],"1999-06",[13],[122,123,67,93],"Indinavir sulfate","Nelfinavir mesylate",{"trials":125,"activeCount":8},[],{"trials":127,"activeCount":8},[128,135],{"nctId":129,"briefTitle":130,"status":53,"phases":131,"start":64,"enrollment":132,"conditions":133,"interventions":134},"NCT00005106","A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients",[37],230,[13],[103,58,123,67,93],{"nctId":85,"briefTitle":86,"status":87,"phases":136,"enrollment":89,"conditions":137,"interventions":138},[37],[13],[92,58,59,41,67,93],{"trials":140,"activeCount":8},[],{"intervention":92,"totalTrials":107,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":156,"PHASE4":167,"NA":173},{"trials":144,"activeCount":8},[],{"trials":146,"activeCount":8},[],{"trials":148,"activeCount":8},[149],{"nctId":150,"briefTitle":151,"status":53,"phases":152,"enrollment":55,"conditions":153,"interventions":154},"NCT00002440","A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs",[35],[13],[122,92,58,59,123,155],"Saquinavir",{"trials":157,"activeCount":8},[158],{"nctId":159,"briefTitle":160,"status":87,"phases":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT00009061","Comparison of GW433908\u002FRitonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs",[36],"2000-11",624,[13],[92,58,123,67,166],"GW433908",{"trials":168,"activeCount":8},[169],{"nctId":85,"briefTitle":86,"status":87,"phases":170,"enrollment":89,"conditions":171,"interventions":172},[37],[13],[92,58,59,41,67,93],{"trials":174,"activeCount":8},[],{"intervention":102,"totalTrials":21,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":191,"NA":197},{"trials":178,"activeCount":8},[],{"trials":180,"activeCount":8},[],{"trials":182,"activeCount":8},[],{"trials":184,"activeCount":8},[185],{"nctId":186,"briefTitle":187,"status":87,"phases":188,"enrollment":132,"conditions":189,"interventions":190},"NCT00004981","Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)",[36],[13],[102,103,58],{"trials":192,"activeCount":8},[193],{"nctId":95,"briefTitle":96,"status":53,"phases":194,"start":98,"enrollment":99,"conditions":195,"interventions":196},[37],[13],[102,103,58,41],{"trials":198,"activeCount":8},[],{"intervention":82,"totalTrials":24,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":8},[],{"trials":204,"activeCount":8},[],{"trials":206,"activeCount":8},[],{"trials":208,"activeCount":8},[],{"trials":210,"activeCount":8},[211],{"nctId":74,"briefTitle":75,"status":53,"phases":212,"completion":77,"start":78,"enrollment":79,"conditions":213,"interventions":214},[37],[13],[82,58,41,83],{"trials":216,"activeCount":8},[],{"intervention":122,"totalTrials":218,"cells":219},7,{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":231,"PHASE3":256,"PHASE4":272,"NA":274},{"trials":221,"activeCount":8},[],{"trials":223,"activeCount":8},[224],{"nctId":225,"briefTitle":226,"status":53,"phases":227,"enrollment":228,"conditions":229,"interventions":230},"NCT00002372","A Study of 141W94 in Combination With Other Anti-HIV Drugs",[34],48,[13],[122,59,123,155],{"trials":232,"activeCount":8},[233,241,245,249],{"nctId":234,"briefTitle":235,"status":53,"phases":236,"start":237,"enrollment":238,"conditions":239,"interventions":240},"NCT00002423","A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir",[35],"1999-03",100,[13],[122,58,59,123,67],{"nctId":150,"briefTitle":151,"status":53,"phases":242,"enrollment":55,"conditions":243,"interventions":244},[35],[13],[122,92,58,59,123,155],{"nctId":116,"briefTitle":117,"status":53,"phases":246,"start":119,"conditions":247,"interventions":248},[35],[13],[122,123,67,93],{"nctId":250,"briefTitle":251,"status":53,"phases":252,"enrollment":253,"conditions":254,"interventions":255},"NCT00002233","A Study of a Combination of Four Drugs in Patients With Recent HIV Infection",[35],30,[13],[122,58,59,67],{"trials":257,"activeCount":8},[258,265],{"nctId":259,"briefTitle":260,"status":53,"phases":261,"enrollment":262,"conditions":263,"interventions":264},"NCT00002202","A Comparison of 141W94 and Indinavir in HIV-Infected Patients",[36],460,[13],[122,59],{"nctId":266,"briefTitle":267,"status":53,"phases":268,"enrollment":269,"conditions":270,"interventions":271},"NCT00002199","A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC\u002FZDV\u002F1592U89 and 3TC\u002FZDV\u002FIDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.",[36],550,[13],[122,103,58],{"trials":273,"activeCount":8},[],{"trials":275,"activeCount":8},[],{"intervention":166,"totalTrials":21,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":297,"NA":299},{"trials":279,"activeCount":8},[],{"trials":281,"activeCount":8},[],{"trials":283,"activeCount":8},[],{"trials":285,"activeCount":8},[286,293],{"nctId":287,"briefTitle":288,"status":87,"phases":289,"start":162,"enrollment":290,"conditions":291,"interventions":292},"NCT00008554","Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy",[36],210,[13],[58,123,67,166],{"nctId":159,"briefTitle":160,"status":87,"phases":294,"start":162,"enrollment":163,"conditions":295,"interventions":296},[36],[13],[92,58,123,67,166],{"trials":298,"activeCount":8},[],{"trials":300,"activeCount":8},[],{"intervention":302,"totalTrials":21,"cells":303},"Pentamidine isethionate",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":317,"PHASE4":326,"NA":328},{"trials":305,"activeCount":8},[],{"trials":307,"activeCount":8},[],{"trials":309,"activeCount":8},[310],{"nctId":311,"briefTitle":312,"status":53,"phases":313,"conditions":314,"interventions":315},"NCT00001996","A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim \u002F Sulfamethoxazole",[35],[18,13],[316,302],"Atovaquone",{"trials":318,"activeCount":8},[319],{"nctId":320,"briefTitle":321,"status":53,"phases":322,"enrollment":323,"conditions":324,"interventions":325},"NCT00002340","A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP\u002FSMX",[36],615,[18,13],[316,302],{"trials":327,"activeCount":8},[],{"trials":329,"activeCount":8},[],{"intervention":331,"totalTrials":24,"cells":332},"Netivudine",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":350,"NA":352},{"trials":334,"activeCount":8},[],{"trials":336,"activeCount":8},[],{"trials":338,"activeCount":8},[],{"trials":340,"activeCount":8},[341],{"nctId":342,"briefTitle":343,"status":53,"phases":344,"enrollment":345,"conditions":346,"interventions":348},"NCT00002315","A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems",[36],400,[13,347],"Chickenpox",[331,349],"Acyclovir",{"trials":351,"activeCount":8},[],{"trials":353,"activeCount":8},[],{"intervention":155,"totalTrials":21,"cells":355},{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":364,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[360],{"nctId":225,"briefTitle":226,"status":53,"phases":361,"enrollment":228,"conditions":362,"interventions":363},[34],[13],[122,59,123,155],{"trials":365,"activeCount":8},[366],{"nctId":150,"briefTitle":151,"status":53,"phases":367,"enrollment":55,"conditions":368,"interventions":369},[35],[13],[122,92,58,59,123,155],{"trials":371,"activeCount":8},[],{"trials":373,"activeCount":8},[],{"trials":375,"activeCount":8},[],{"intervention":377,"totalTrials":24,"cells":378},"Ranitidine hydrochloride",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":392,"PHASE4":394,"NA":396},{"trials":380,"activeCount":8},[],{"trials":382,"activeCount":8},[],{"trials":384,"activeCount":8},[385],{"nctId":386,"briefTitle":387,"status":53,"phases":388,"enrollment":389,"conditions":390,"interventions":391},"NCT00002106","A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells\u002Fmm3",[35],104,[13],[377],{"trials":393,"activeCount":8},[],{"trials":395,"activeCount":8},[],{"trials":397,"activeCount":8},[],{"intervention":399,"totalTrials":24,"cells":400},"Interferon alfa-n1",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":402,"activeCount":8},[],{"trials":404,"activeCount":8},[],{"trials":406,"activeCount":8},[407],{"nctId":408,"briefTitle":409,"status":53,"phases":410,"enrollment":411,"conditions":412,"interventions":413},"NCT00002086","A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection",[35],256,[13],[68,414,399],"Zalcitabine",{"trials":416,"activeCount":8},[],{"trials":418,"activeCount":8},[],{"trials":420,"activeCount":8},[],{"intervention":422,"totalTrials":24,"cells":423},"Maribavir",{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":425,"activeCount":8},[],{"trials":427,"activeCount":8},[428],{"nctId":429,"briefTitle":430,"status":53,"phases":431,"enrollment":432,"conditions":433,"interventions":434},"NCT00002373","The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients",[34],56,[30,13],[422],{"trials":436,"activeCount":8},[],{"trials":438,"activeCount":8},[],{"trials":440,"activeCount":8},[],{"trials":442,"activeCount":8},[],{"intervention":444,"totalTrials":24,"cells":445},"Raluridine",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":447,"activeCount":8},[],{"trials":449,"activeCount":8},[450],{"nctId":451,"briefTitle":452,"status":53,"phases":453,"enrollment":99,"conditions":454,"interventions":455},"NCT00002338","The Safety and Effectiveness of 935U83 in HIV-Infected Patients",[34],[13],[444],{"trials":457,"activeCount":8},[],{"trials":459,"activeCount":8},[],{"trials":461,"activeCount":8},[],{"trials":463,"activeCount":8},[],{"intervention":465,"totalTrials":24,"cells":466},"Emtricitabine",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":468,"activeCount":8},[],{"trials":470,"activeCount":8},[471],{"nctId":472,"briefTitle":473,"status":53,"phases":474,"enrollment":475,"conditions":476,"interventions":477},"NCT00002335","The Safety and Effectiveness of 524W91",[34],18,[13],[465],{"trials":479,"activeCount":8},[],{"trials":481,"activeCount":8},[],{"trials":483,"activeCount":8},[],{"trials":485,"activeCount":8},[],{"intervention":58,"totalTrials":487,"cells":488},28,{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":512,"PHASE3":542,"PHASE4":592,"NA":618},{"trials":490,"activeCount":8},[],{"trials":492,"activeCount":8},[493,499,505],{"nctId":494,"briefTitle":495,"status":53,"phases":496,"conditions":497,"interventions":498},"NCT00002198","A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients",[34],[13],[58],{"nctId":500,"briefTitle":501,"status":53,"phases":502,"enrollment":228,"conditions":503,"interventions":504},"NCT00002388","A Study of 1592U89 in HIV-Infected Patients",[34],[13],[58],{"nctId":506,"briefTitle":507,"status":53,"phases":508,"enrollment":509,"conditions":510,"interventions":511},"NCT00002183","A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection",[34],60,[13],[58,59,67,68],{"trials":513,"activeCount":8},[514,520,524,528,532,536],{"nctId":515,"briefTitle":516,"status":53,"phases":517,"enrollment":99,"conditions":518,"interventions":519},"NCT00002364","A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs",[35],[13],[58],{"nctId":51,"briefTitle":52,"status":53,"phases":521,"enrollment":55,"conditions":522,"interventions":523},[35],[13],[58,59,41],{"nctId":234,"briefTitle":235,"status":53,"phases":525,"start":237,"enrollment":238,"conditions":526,"interventions":527},[35],[13],[122,58,59,123,67],{"nctId":150,"briefTitle":151,"status":53,"phases":529,"enrollment":55,"conditions":530,"interventions":531},[35],[13],[122,92,58,59,123,155],{"nctId":250,"briefTitle":251,"status":53,"phases":533,"enrollment":253,"conditions":534,"interventions":535},[35],[13],[122,58,59,67],{"nctId":537,"briefTitle":538,"status":53,"phases":539,"conditions":540,"interventions":541},"NCT00002390","A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients",[35],[13],[58],{"trials":543,"activeCount":8},[544,548,554,560,564,568,574,578,585],{"nctId":287,"briefTitle":288,"status":87,"phases":545,"start":162,"enrollment":290,"conditions":546,"interventions":547},[36],[13],[58,123,67,166],{"nctId":549,"briefTitle":550,"status":53,"phases":551,"enrollment":290,"conditions":552,"interventions":553},"NCT00002389","The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs",[36],[13],[58,67,68],{"nctId":555,"briefTitle":556,"status":53,"phases":557,"conditions":558,"interventions":559},"NCT00002163","A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex",[36],[20,13],[58],{"nctId":159,"briefTitle":160,"status":87,"phases":561,"start":162,"enrollment":163,"conditions":562,"interventions":563},[36],[13],[92,58,123,67,166],{"nctId":186,"briefTitle":187,"status":87,"phases":565,"enrollment":132,"conditions":566,"interventions":567},[36],[13],[102,103,58],{"nctId":569,"briefTitle":570,"status":53,"phases":571,"conditions":572,"interventions":573},"NCT00002391","The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs",[36],[13],[58,67,68],{"nctId":266,"briefTitle":267,"status":53,"phases":575,"enrollment":269,"conditions":576,"interventions":577},[36],[13],[122,103,58],{"nctId":579,"briefTitle":580,"status":53,"phases":581,"start":582,"conditions":583,"interventions":584},"NCT00002245","A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients",[36],"1999-04",[13],[58,59,67],{"nctId":586,"briefTitle":587,"status":53,"phases":588,"enrollment":589,"conditions":590,"interventions":591},"NCT00002409","The Effect of Teaching HIV-Infected Patients About HIV and Treatment",[36],200,[13],[103,58],{"trials":593,"activeCount":8},[594,598,602,606,614],{"nctId":129,"briefTitle":130,"status":53,"phases":595,"start":64,"enrollment":132,"conditions":596,"interventions":597},[37],[13],[103,58,123,67,93],{"nctId":74,"briefTitle":75,"status":53,"phases":599,"completion":77,"start":78,"enrollment":79,"conditions":600,"interventions":601},[37],[13],[82,58,41,83],{"nctId":85,"briefTitle":86,"status":87,"phases":603,"enrollment":89,"conditions":604,"interventions":605},[37],[13],[92,58,59,41,67,93],{"nctId":607,"briefTitle":608,"status":53,"phases":609,"start":610,"enrollment":238,"conditions":611,"interventions":613},"NCT00005764","A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients",[37],"2000-05",[13,612],"Lipodystrophy",[103,58,67],{"nctId":95,"briefTitle":96,"status":53,"phases":615,"start":98,"enrollment":99,"conditions":616,"interventions":617},[37],[13],[102,103,58,41],{"trials":619,"activeCount":8},[620,627,633,639,645],{"nctId":621,"briefTitle":622,"status":53,"phases":623,"enrollment":624,"conditions":625,"interventions":626},"NCT00002197","A Study of 1592U89 in HIV-Infected Children",[38],250,[13],[58],{"nctId":628,"briefTitle":629,"status":53,"phases":630,"conditions":631,"interventions":632},"NCT00002205","An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen",[38],[13],[58,59],{"nctId":634,"briefTitle":635,"status":53,"phases":636,"conditions":637,"interventions":638},"NCT00002217","A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs",[38],[13],[103,58,59],{"nctId":640,"briefTitle":641,"status":53,"phases":642,"conditions":643,"interventions":644},"NCT00002216","A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment",[38],[13],[103,58,59,123],{"nctId":646,"briefTitle":647,"status":53,"phases":648,"conditions":649,"interventions":650},"NCT00002200","A Study of 1592U89 in HIV-Infected Adults",[38],[13],[58],{"intervention":68,"totalTrials":652,"cells":653},26,{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":668,"PHASE3":678,"PHASE4":709,"NA":711},{"trials":655,"activeCount":8},[],{"trials":657,"activeCount":8},[658,664],{"nctId":659,"briefTitle":660,"status":53,"phases":661,"conditions":662,"interventions":663},"NCT00002014","A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)",[34],[13],[68,83],{"nctId":506,"briefTitle":507,"status":53,"phases":665,"enrollment":509,"conditions":666,"interventions":667},[34],[13],[58,59,67,68],{"trials":669,"activeCount":8},[670,674],{"nctId":408,"briefTitle":409,"status":53,"phases":671,"enrollment":411,"conditions":672,"interventions":673},[35],[13],[68,414,399],{"nctId":61,"briefTitle":62,"status":53,"phases":675,"start":64,"conditions":676,"interventions":677},[35],[13],[41,67,68],{"trials":679,"activeCount":8},[680,684,691,698,702],{"nctId":549,"briefTitle":550,"status":53,"phases":681,"enrollment":290,"conditions":682,"interventions":683},[36],[13],[58,67,68],{"nctId":685,"briefTitle":686,"status":53,"phases":687,"enrollment":688,"conditions":689,"interventions":690},"NCT00002195","A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients",[36],290,[13],[59,67,68],{"nctId":692,"briefTitle":693,"status":53,"phases":694,"enrollment":695,"conditions":696,"interventions":697},"NCT00002320","A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past",[36],320,[13],[67,68],{"nctId":569,"briefTitle":570,"status":53,"phases":699,"conditions":700,"interventions":701},[36],[13],[58,67,68],{"nctId":703,"briefTitle":704,"status":53,"phases":705,"enrollment":706,"conditions":707,"interventions":708},"NCT00002436","The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT",[36],325,[13],[67,68,414],{"trials":710,"activeCount":8},[],{"trials":712,"activeCount":8},[713,719,725,731,737,743,749,755,761,768,775,781,787,793,800,806,813],{"nctId":714,"briefTitle":715,"status":53,"phases":716,"conditions":717,"interventions":718},"NCT00002285","A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS",[38],[13],[68],{"nctId":720,"briefTitle":721,"status":53,"phases":722,"conditions":723,"interventions":724},"NCT00002290","The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection",[38],[13],[68,349],{"nctId":726,"briefTitle":727,"status":53,"phases":728,"conditions":729,"interventions":730},"NCT00002047","Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure",[38],[13,26],[68],{"nctId":732,"briefTitle":733,"status":53,"phases":734,"conditions":735,"interventions":736},"NCT00002045","A Prospective Double-Blind Study of Retrovir in Early HIV Infection",[38],[13],[68],{"nctId":738,"briefTitle":739,"status":53,"phases":740,"conditions":741,"interventions":742},"NCT00002020","Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC",[38],[13],[68],{"nctId":744,"briefTitle":745,"status":53,"phases":746,"conditions":747,"interventions":748},"NCT00002203","A Study of Two Anti-HIV Drug Combinations",[38],[13],[103,67,68],{"nctId":750,"briefTitle":751,"status":53,"phases":752,"conditions":753,"interventions":754},"NCT00002288","The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System",[38],[13],[68],{"nctId":756,"briefTitle":757,"status":53,"phases":758,"conditions":759,"interventions":760},"NCT00002046","A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC",[38],[13],[68],{"nctId":762,"briefTitle":763,"status":53,"phases":764,"conditions":765,"interventions":767},"NCT00002284","A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant",[38],[766,13],"Lymphoma, Non-Hodgkin",[68],{"nctId":769,"briefTitle":770,"status":53,"phases":771,"conditions":772,"interventions":774},"NCT00002286","A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients",[38],[13,773],"Psoriasis",[68],{"nctId":776,"briefTitle":777,"status":53,"phases":778,"conditions":779,"interventions":780},"NCT00002063","Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)",[38],[13],[68],{"nctId":782,"briefTitle":783,"status":53,"phases":784,"conditions":785,"interventions":786},"NCT00002023","An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2",[38],[13],[68],{"nctId":788,"briefTitle":789,"status":53,"phases":790,"conditions":791,"interventions":792},"NCT00002001","The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease",[38],[13],[68,414,83],{"nctId":794,"briefTitle":795,"status":53,"phases":796,"conditions":797,"interventions":799},"NCT00002044","A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases",[38],[20,798,13],"Neuromuscular Diseases",[68],{"nctId":801,"briefTitle":802,"status":53,"phases":803,"conditions":804,"interventions":805},"NCT00002287","A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus",[38],[13],[68],{"nctId":807,"briefTitle":808,"status":53,"phases":809,"conditions":810,"interventions":812},"NCT00002048","The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)",[38],[811,13],"Lymphatic Disease",[68],{"nctId":814,"briefTitle":815,"status":53,"phases":816,"conditions":817,"interventions":818},"NCT00002108","3TC (Lamivudine; GR109714X) Open-Label Program",[38],[13],[67,68],{"intervention":67,"totalTrials":475,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":829,"PHASE3":847,"PHASE4":881,"NA":895},{"trials":822,"activeCount":8},[],{"trials":824,"activeCount":8},[825],{"nctId":506,"briefTitle":507,"status":53,"phases":826,"enrollment":509,"conditions":827,"interventions":828},[34],[13],[58,59,67,68],{"trials":830,"activeCount":8},[831,835,839,843],{"nctId":234,"briefTitle":235,"status":53,"phases":832,"start":237,"enrollment":238,"conditions":833,"interventions":834},[35],[13],[122,58,59,123,67],{"nctId":61,"briefTitle":62,"status":53,"phases":836,"start":64,"conditions":837,"interventions":838},[35],[13],[41,67,68],{"nctId":116,"briefTitle":117,"status":53,"phases":840,"start":119,"conditions":841,"interventions":842},[35],[13],[122,123,67,93],{"nctId":250,"briefTitle":251,"status":53,"phases":844,"enrollment":253,"conditions":845,"interventions":846},[35],[13],[122,58,59,67],{"trials":848,"activeCount":8},[849,853,857,861,865,869,873,877],{"nctId":287,"briefTitle":288,"status":87,"phases":850,"start":162,"enrollment":290,"conditions":851,"interventions":852},[36],[13],[58,123,67,166],{"nctId":549,"briefTitle":550,"status":53,"phases":854,"enrollment":290,"conditions":855,"interventions":856},[36],[13],[58,67,68],{"nctId":159,"briefTitle":160,"status":87,"phases":858,"start":162,"enrollment":163,"conditions":859,"interventions":860},[36],[13],[92,58,123,67,166],{"nctId":685,"briefTitle":686,"status":53,"phases":862,"enrollment":688,"conditions":863,"interventions":864},[36],[13],[59,67,68],{"nctId":692,"briefTitle":693,"status":53,"phases":866,"enrollment":695,"conditions":867,"interventions":868},[36],[13],[67,68],{"nctId":569,"briefTitle":570,"status":53,"phases":870,"conditions":871,"interventions":872},[36],[13],[58,67,68],{"nctId":703,"briefTitle":704,"status":53,"phases":874,"enrollment":706,"conditions":875,"interventions":876},[36],[13],[67,68,414],{"nctId":579,"briefTitle":580,"status":53,"phases":878,"start":582,"conditions":879,"interventions":880},[36],[13],[58,59,67],{"trials":882,"activeCount":8},[883,887,891],{"nctId":129,"briefTitle":130,"status":53,"phases":884,"start":64,"enrollment":132,"conditions":885,"interventions":886},[37],[13],[103,58,123,67,93],{"nctId":85,"briefTitle":86,"status":87,"phases":888,"enrollment":89,"conditions":889,"interventions":890},[37],[13],[92,58,59,41,67,93],{"nctId":607,"briefTitle":608,"status":53,"phases":892,"start":610,"enrollment":238,"conditions":893,"interventions":894},[37],[13,612],[103,58,67],{"trials":896,"activeCount":8},[897,901],{"nctId":744,"briefTitle":745,"status":53,"phases":898,"conditions":899,"interventions":900},[38],[13],[103,67,68],{"nctId":814,"briefTitle":815,"status":53,"phases":902,"conditions":903,"interventions":904},[38],[13],[67,68],{"intervention":59,"totalTrials":906,"cells":907},16,{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":920,"PHASE3":938,"PHASE4":958,"NA":964},{"trials":909,"activeCount":8},[],{"trials":911,"activeCount":8},[912,916],{"nctId":506,"briefTitle":507,"status":53,"phases":913,"enrollment":509,"conditions":914,"interventions":915},[34],[13],[58,59,67,68],{"nctId":225,"briefTitle":226,"status":53,"phases":917,"enrollment":228,"conditions":918,"interventions":919},[34],[13],[122,59,123,155],{"trials":921,"activeCount":8},[922,926,930,934],{"nctId":51,"briefTitle":52,"status":53,"phases":923,"enrollment":55,"conditions":924,"interventions":925},[35],[13],[58,59,41],{"nctId":234,"briefTitle":235,"status":53,"phases":927,"start":237,"enrollment":238,"conditions":928,"interventions":929},[35],[13],[122,58,59,123,67],{"nctId":150,"briefTitle":151,"status":53,"phases":931,"enrollment":55,"conditions":932,"interventions":933},[35],[13],[122,92,58,59,123,155],{"nctId":250,"briefTitle":251,"status":53,"phases":935,"enrollment":253,"conditions":936,"interventions":937},[35],[13],[122,58,59,67],{"trials":939,"activeCount":8},[940,944,950,954],{"nctId":259,"briefTitle":260,"status":53,"phases":941,"enrollment":262,"conditions":942,"interventions":943},[36],[13],[122,59],{"nctId":945,"briefTitle":946,"status":53,"phases":947,"enrollment":290,"conditions":948,"interventions":949},"NCT00002193","Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors",[36],[13],[59],{"nctId":685,"briefTitle":686,"status":53,"phases":951,"enrollment":688,"conditions":952,"interventions":953},[36],[13],[59,67,68],{"nctId":579,"briefTitle":580,"status":53,"phases":955,"start":582,"conditions":956,"interventions":957},[36],[13],[58,59,67],{"trials":959,"activeCount":8},[960],{"nctId":85,"briefTitle":86,"status":87,"phases":961,"enrollment":89,"conditions":962,"interventions":963},[37],[13],[92,58,59,41,67,93],{"trials":965,"activeCount":8},[966,972,976,982,986],{"nctId":967,"briefTitle":968,"status":53,"phases":969,"conditions":970,"interventions":971},"NCT00002417","A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications",[38],[13],[59],{"nctId":628,"briefTitle":629,"status":53,"phases":973,"conditions":974,"interventions":975},[38],[13],[58,59],{"nctId":977,"briefTitle":978,"status":53,"phases":979,"conditions":980,"interventions":981},"NCT00002405","A Study of Amprenavir in HIV-Infected Patients",[38],[13],[59],{"nctId":634,"briefTitle":635,"status":53,"phases":983,"conditions":984,"interventions":985},[38],[13],[103,58,59],{"nctId":640,"briefTitle":641,"status":53,"phases":987,"conditions":988,"interventions":989},[38],[13],[103,58,59,123],{"intervention":103,"totalTrials":991,"cells":992},9,{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1013,"NA":1027},{"trials":994,"activeCount":8},[],{"trials":996,"activeCount":8},[],{"trials":998,"activeCount":8},[],{"trials":1000,"activeCount":8},[1001,1005,1009],{"nctId":186,"briefTitle":187,"status":87,"phases":1002,"enrollment":132,"conditions":1003,"interventions":1004},[36],[13],[102,103,58],{"nctId":266,"briefTitle":267,"status":53,"phases":1006,"enrollment":269,"conditions":1007,"interventions":1008},[36],[13],[122,103,58],{"nctId":586,"briefTitle":587,"status":53,"phases":1010,"enrollment":589,"conditions":1011,"interventions":1012},[36],[13],[103,58],{"trials":1014,"activeCount":8},[1015,1019,1023],{"nctId":129,"briefTitle":130,"status":53,"phases":1016,"start":64,"enrollment":132,"conditions":1017,"interventions":1018},[37],[13],[103,58,123,67,93],{"nctId":607,"briefTitle":608,"status":53,"phases":1020,"start":610,"enrollment":238,"conditions":1021,"interventions":1022},[37],[13,612],[103,58,67],{"nctId":95,"briefTitle":96,"status":53,"phases":1024,"start":98,"enrollment":99,"conditions":1025,"interventions":1026},[37],[13],[102,103,58,41],{"trials":1028,"activeCount":8},[1029,1033,1037],{"nctId":744,"briefTitle":745,"status":53,"phases":1030,"conditions":1031,"interventions":1032},[38],[13],[103,67,68],{"nctId":634,"briefTitle":635,"status":53,"phases":1034,"conditions":1035,"interventions":1036},[38],[13],[103,58,59],{"nctId":640,"briefTitle":641,"status":53,"phases":1038,"conditions":1039,"interventions":1040},[38],[13],[103,58,59,123],{"intervention":123,"totalTrials":1042,"cells":1043},8,{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1052,"PHASE3":1066,"PHASE4":1076,"NA":1082},{"trials":1045,"activeCount":8},[],{"trials":1047,"activeCount":8},[1048],{"nctId":225,"briefTitle":226,"status":53,"phases":1049,"enrollment":228,"conditions":1050,"interventions":1051},[34],[13],[122,59,123,155],{"trials":1053,"activeCount":8},[1054,1058,1062],{"nctId":234,"briefTitle":235,"status":53,"phases":1055,"start":237,"enrollment":238,"conditions":1056,"interventions":1057},[35],[13],[122,58,59,123,67],{"nctId":150,"briefTitle":151,"status":53,"phases":1059,"enrollment":55,"conditions":1060,"interventions":1061},[35],[13],[122,92,58,59,123,155],{"nctId":116,"briefTitle":117,"status":53,"phases":1063,"start":119,"conditions":1064,"interventions":1065},[35],[13],[122,123,67,93],{"trials":1067,"activeCount":8},[1068,1072],{"nctId":287,"briefTitle":288,"status":87,"phases":1069,"start":162,"enrollment":290,"conditions":1070,"interventions":1071},[36],[13],[58,123,67,166],{"nctId":159,"briefTitle":160,"status":87,"phases":1073,"start":162,"enrollment":163,"conditions":1074,"interventions":1075},[36],[13],[92,58,123,67,166],{"trials":1077,"activeCount":8},[1078],{"nctId":129,"briefTitle":130,"status":53,"phases":1079,"start":64,"enrollment":132,"conditions":1080,"interventions":1081},[37],[13],[103,58,123,67,93],{"trials":1083,"activeCount":8},[1084],{"nctId":640,"briefTitle":641,"status":53,"phases":1085,"conditions":1086,"interventions":1087},[38],[13],[103,58,59,123],{"intervention":349,"totalTrials":42,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1102,"NA":1104},{"trials":1091,"activeCount":8},[],{"trials":1093,"activeCount":8},[],{"trials":1095,"activeCount":8},[],{"trials":1097,"activeCount":8},[1098],{"nctId":342,"briefTitle":343,"status":53,"phases":1099,"enrollment":345,"conditions":1100,"interventions":1101},[36],[13,347],[331,349],{"trials":1103,"activeCount":8},[],{"trials":1105,"activeCount":8},[1106,1110,1117,1124],{"nctId":720,"briefTitle":721,"status":53,"phases":1107,"conditions":1108,"interventions":1109},[38],[13],[68,349],{"nctId":1111,"briefTitle":1112,"status":53,"phases":1113,"conditions":1114,"interventions":1115},"NCT00002084","A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients",[38],[15,13],[1116,349],"Valacyclovir hydrochloride",{"nctId":1118,"briefTitle":1119,"status":53,"phases":1120,"conditions":1121,"interventions":1123},"NCT00002026","Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)",[38],[1122,13],"Leukoplakia, Hairy",[349],{"nctId":1125,"briefTitle":1126,"status":53,"phases":1127,"conditions":1128,"interventions":1129},"NCT00002000","A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients",[38],[15,13],[1116,349],{"intervention":316,"totalTrials":42,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1142,"PHASE4":1148,"NA":1150},{"trials":1133,"activeCount":8},[],{"trials":1135,"activeCount":8},[],{"trials":1137,"activeCount":8},[1138],{"nctId":311,"briefTitle":312,"status":53,"phases":1139,"conditions":1140,"interventions":1141},[35],[18,13],[316,302],{"trials":1143,"activeCount":8},[1144],{"nctId":320,"briefTitle":321,"status":53,"phases":1145,"enrollment":323,"conditions":1146,"interventions":1147},[36],[18,13],[316,302],{"trials":1149,"activeCount":8},[],{"trials":1151,"activeCount":8},[1152,1158,1164],{"nctId":1153,"briefTitle":1154,"status":53,"phases":1155,"conditions":1156,"interventions":1157},"NCT00001994","A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine",[38],[28,13],[316],{"nctId":1159,"briefTitle":1160,"status":53,"phases":1161,"conditions":1162,"interventions":1163},"NCT00001990","An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and\u002For Unresponsive to Therapy With Trimethoprim\u002FSulfamethoxazole and Parenteral Pentamidine",[38],[18,13],[316],{"nctId":1165,"briefTitle":1166,"status":53,"phases":1167,"conditions":1168,"interventions":1169},"NCT00001991","A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia",[38],[18,13],[316],{"intervention":1116,"totalTrials":16,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1178,"PHASE4":1186,"NA":1188},{"trials":1173,"activeCount":8},[],{"trials":1175,"activeCount":8},[],{"trials":1177,"activeCount":8},[],{"trials":1179,"activeCount":8},[1180],{"nctId":1181,"briefTitle":1182,"status":87,"phases":1183,"start":119,"conditions":1184,"interventions":1185},"NCT00005663","A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients",[36],[15,13,23],[1116],{"trials":1187,"activeCount":8},[],{"trials":1189,"activeCount":8},[1190,1194,1198],{"nctId":1111,"briefTitle":1112,"status":53,"phases":1191,"conditions":1192,"interventions":1193},[38],[15,13],[1116,349],{"nctId":1125,"briefTitle":1126,"status":53,"phases":1195,"conditions":1196,"interventions":1197},[38],[15,13],[1116,349],{"nctId":1199,"briefTitle":1200,"status":53,"phases":1201,"enrollment":253,"conditions":1202,"interventions":1203},"NCT00002404","The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients",[38],[15,13],[1116],{"intervention":83,"totalTrials":107,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1224},{"trials":1207,"activeCount":8},[],{"trials":1209,"activeCount":8},[1210],{"nctId":659,"briefTitle":660,"status":53,"phases":1211,"conditions":1212,"interventions":1213},[34],[13],[68,83],{"trials":1215,"activeCount":8},[],{"trials":1217,"activeCount":8},[],{"trials":1219,"activeCount":8},[1220],{"nctId":74,"briefTitle":75,"status":53,"phases":1221,"completion":77,"start":78,"enrollment":79,"conditions":1222,"interventions":1223},[37],[13],[82,58,41,83],{"trials":1225,"activeCount":8},[1226],{"nctId":788,"briefTitle":789,"status":53,"phases":1227,"conditions":1228,"interventions":1229},[38],[13],[68,414,83],{"intervention":414,"totalTrials":107,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1242,"PHASE4":1248,"NA":1250},{"trials":1233,"activeCount":8},[],{"trials":1235,"activeCount":8},[],{"trials":1237,"activeCount":8},[1238],{"nctId":408,"briefTitle":409,"status":53,"phases":1239,"enrollment":411,"conditions":1240,"interventions":1241},[35],[13],[68,414,399],{"trials":1243,"activeCount":8},[1244],{"nctId":703,"briefTitle":704,"status":53,"phases":1245,"enrollment":706,"conditions":1246,"interventions":1247},[36],[13],[67,68,414],{"trials":1249,"activeCount":8},[],{"trials":1251,"activeCount":8},[1252],{"nctId":788,"briefTitle":789,"status":53,"phases":1253,"conditions":1254,"interventions":1255},[38],[13],[68,414,83]]